Lanreotide Autogel (LAN) 120 mg in Patients with Progressive Enteropancreatic (EP-) NETs: Data from the CLARINET Open-Label Extension (OLE) Study

#1185

Introduction: In the CLARINET core study, LAN 120 mg significantly prolonged PFS vs placebo (PBO) in metastatic grade 1 or 2 EP-NETs.

Aim(s): To summarise efficacy and safety outcomes from the OLE study for patients entering after PD on PBO.

Materials and methods: Patients in the core study had: metastatic well/moderately differentiated non-functioning EP-NETs with Ki-67 <10%; no prior medical therapy in last 6 months. Patients received LAN 120 mg/PBO every 4 wks for 96 wks or until PD/death (RECIST 1.0) in the core study. Patients could enter the open-label LAN-only OLE (NCT00842348) if they had PD with PBO during core study or SD with LAN or PBO at core-study end. They received LAN 120 mg until (further) PD/death. Data are from the pre-planned interim analysis.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,

Keywords: antitumour effects, progressive disease, lanreotide,